1) Liu W, Tang F, Fontanet A, Zhan L, Zhao QM, Zhang PH, Wu XM, Zuo SQ, Baril L, Vabret A, Xin ZT, Shao YM, Yang H, Cao WC. Long-term SARS coronavirus excretion from patient cohort, China. Emerg Infect Dis. 2004;10:1841-3. Abstract

2) Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, Mohamed MK. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology. 2004;40:1434-41. Abstract

3) Vray M, Girault D, Hoog-Labouret N, Porcher R, Thalabard JC; Round Table No. 1, Giens XIX. Methodology for small clinical trials.Therapie. 2004;59:273-9, 281-6. Abstract

4) Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, Vray M, Prevot MH, Leleu G, Benech H. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS. 2004;18:181-7. Abstract

5) El Hasnaoui A, Vray M, Blin P, Nachit-Ouinekh F, Boureau F; HEMISHERE study group. Assessment of migraine severity using the MIGSEV scale: relationship to migraine features and quality of life. Cephalalgia. 2004;24:262-70. Abstract

6) Naniche D, Garenne M, Rae C, Manchester M, Buchta R, Brodine SK, Oldston MBA. Decline of measles virus-specific CD4 T-cell memory in vaccinated humans. J Infect Dis, 2004;190:1387-1395. Abstract

7) Baril L, Briles DE, Crozier P, King J, Punar M, Hollingshead SK, McCormick JB. Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine. 2004 ;23:789-93. Abstract

8) Souvignet C, Frebourg G, Baril L. Identifying patients with severe hospital-acquired infections due to Staphylococcus aureus by using the Healthcare Cost and Utilization Project (HCUP): problems and pitfalls. Infect Control Hosp Epidemiol. 2004;25:450-1. Abstract

9) Baril L, Briles DE, Crozier P, King JD, Hollingshead SK, Murphy TF, McCormick JB. Natural materno-fetal transfer of antibodies to PspA and to PsaA. Clin Exp Immunol. 2004;135:474-7. Abstract

10) Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett. 2004;355:226-30. Abstract

11) Beq S, Fontanet A, Theze J, Colle JH. IL-7 and Flt-3L plasma levels are increased during highly active antiretroviral therapy-associated IL-2 therapy. AIDS. 2004 21;18:2089-91. Abstract

12) Eyob G, Guebrexabher H, Lemma E, Wolday D, Gebeyehu M, Abate G, Rigouts L, van Soolingen D, Fontanet A, Sanders E, Dorigo-Zetsma JW. Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up. Int J Tuberc Lung Dis. 2004;8:1388-91. Asbtract

13) Nacher M, Silachamroon U, Singhasivanon P, Wilairatana P, Phumratanaprapin W, Fontanet A, Looareesuwan S. Risk factors for Plasmodium vivax gametocyte carriage in Thailand. Am J Trop Med Hyg. 2004;71:693-695. Abstract

14) Dromer F, Mathoulin-Pélissier S, Fontanet A, Ronin O, Dupont B, Lortholary O, and the French Cryptococcosis Study Group. Epidemiology of cryptococcosis in France (1985-2001): analysis of 2,120 cases from a national Surveillance. AIDS 2004;18:555-62. Abstract

15) Nacher M, Silachamroon U, Singhasivanon P, Wilairatana P, Treeprasertsuk S, Fontanet A, Looareesuwan S. An open comparison between artesunate and chloroquine against Plasmodium vivax gametocytes. Antimicrobial Agents and Chemotherapy 2004;48:2751-2. Abstract

16) Beq S, Rannou MT, Fontanet A, Delfraissy JF, Theze J, Colle JH. HIV infection: pre-highly active antiretroviral therapy IL-7 plasma levels correlate with long-term CD4 cell count increase after treatment. AIDS. 2004 ;20:563-5. Abstract

17) Garenne M, Micol R, Fontanet A. Reply to 'Unsafe healthcare drives spread of African HIV’. Int J STD AIDS. 2004;15:65-7. Abstract

18) Matsika-Claquin MD, Massanga M, Menard D, Mazi-Nzapako J, Tenegbia JP, Mandeng MJ, Willybiro-Sacko J, Fontanet A, Talarmin A. HIV epidemic in Central African Republic: high prevalence rates in both rural and urban areas. J Med Virol. 2004 ;72:358-62. Abstract

Mis à jour le 10/06/2014


Unité d'Epidémiologie des Maladies Emergentes

Institut Pasteur
25-28 rue du Dr Roux
75724 Paris Cedex 15

Tél : +33 (0)1 40 61 37 66
Fax: +33 (0)1 45 68 88 76

Où nous trouver ?